There are ways practices can take advantage of the delay of Oncology Care First (OCF) to continue learning from their experience in Oncology Care Model (OCM), said Mike Fazio, of Archway Health.
There are ways practices can take advantage of the delay of Oncology Care First (OCF) to continue learning from their experience in Oncology Care Model (OCM), said Mike Fazio, senior vice president of Client Services at Archway Health.
Transcript
With Oncology Care First being delayed, are there ways that practices can take advantage of that delay to take what they've learned while participating in Oncology Care Model to make a smoother transition and be successful?
It's been, I think, positively received, at least from the customers that we support for OCM, that the program has been extended a year. So, that anxiety of a new model, and what that will look like is now pushed back. And so, practices can still use the data that they're getting from CMS for OCM to figure out how to refine their model, what works and what doesn't. It is still a pilot, so that pilot continues for another year.
So, using data to improve quality, which is a component of OCM, there's still time to do that. So, things like is your symptom management tool, really reducing ED [emergency department] visits and hospitalizations? You have more time to look at that and to tweak your model. Introducing palliative care early to increase hospice use at end of life—are those processes working or not? And what can you change? And the same thing with supportive therapies and in using biosimilars. So, are those taking an effect, and can we measure those results? We have more time in data to see are those changes happening and are those levers being moved so that you can address changes in the model?
So, I guess you could use the extra time to refine your model and see what's working and what isn't. So that when OCF is announced, and if it's the right program for you, you can have a better sense of what really worked in OCM. So just given the more time that you have.
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More